• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Ratinal design of drags containing ester bond based on carboxylesterase activity

Research Project

Project/Area Number 12672154
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 医薬分子機能学
Research InstitutionKUMAMOTO UNVERSITY

Principal Investigator

IMAI Teruko  KUMAMOTO UNIVERSITY, PROFESSOR, 薬学部, 教授 (70176478)

Co-Investigator(Kenkyū-buntansha) HOSOKAWA Masakiyo  CHIBA UNIVERSITY, ASSOCIATE PROFESSOR, 薬学部, 助教授 (70181500)
TAKETANE Megumi  KUMAMOTO UNIVERSITY, RESEARCH ASSISTANT, 薬学部, 助手 (10315294)
Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2001: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2000: ¥2,000,000 (Direct Cost: ¥2,000,000)
KeywordsCarboxylesterase / Prodrug / Hydrolysis / Ester bond / Drug design / Intestinal microsomes / Liver microsomes / Isoform
Research Abstract

Mammalian carboxylesterases (CESs, EC3.1.1.1) efficiently catalyze the hydrolysis of a variety of drugs containing ester and amide bonds. CESs are localized in the endoplasmic reticulum and cytosol of a wide variety of organs. A drug containing ester is mainly hydrolyzed in the intestine and the liver after oral administration. However, the substrate specificities for CESs have not been clarified. In the present study, we demonstrated significant species differences of the hydrolytic activity in the intestine and liver. In addition, the CES activity in human intestine and liver microsomes was examined and compared to the human CES isoforms, in order to establish an approach for design of prodrugs. Furthermore, we try to develop a cell culture system to estimate the hydrolysis of a compound containing ester during intestinal absorption.
The ester derivatives of model compounds were stereoselectively converted into parent drugs in the liver and intestine of various species. In vitro hydrolytic activity of human intestine and liver was closer to those of monkey than rat, rabbit and dog. The difference of hydrolytic activity in each tissue of various animals attributes to a diversity of the CES molecule. The hydrolysis activity in human intestine was represented by the HU3 (CES2 family) activity, and that in human liver was represented by the HU1 (CES1 family) activity, in spite of the existence of a multigene family in the liver. The hydrolysis properties for each human CES isoform are important for the design of prodrugs. Furthermore, the feasibility of Caco-2 cell line, the most commonly used cell line for estimation of intestinal absorption, in estimating the hydrolysis of ester drugs during absorption was examined. However, original Caco-2 cell was found to be unsuitable for the estimation of hydrolysis in the intestine, because of the presence of both CES1 and CES2 enzymes. We are now studying the way to control CES enzymes expression in Caco-2 cells.

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • Research Products

    (30 results)

All Other

All Publications (30 results)

  • [Publications] 今井輝子, 小田切優樹: "カルボキシルエステラーゼのキラル代謝に基づく体内動態の種差"シンポジウム「モレキュラー・キラリティ」講演要旨集. 27-30 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 今井輝子, 白石澄廣, 小田切優樹: "A strategy for the immediate-release of indomethacin from a sustained-release preparation using a chitosan hydrolysate"S.T.P. Pharm. Sci.. 10. 57-62 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 今井輝子, 川崎知世, 西山哲之, 小田切優樹: "Comparison of the pharmaceutical properties of sustained-release gel beads prepared by alginate having different molecular size with commercial sustained-release tablet"Pharmazie. 5. 218-222 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 今井輝子, 木村進, 小田切優樹: "Biological properties of low molecular fragmented gelatine and its evaluation as a rapid absorptive additive in human volunteers"S.T.P. Pharm. Sci. 10. 321-326 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 山田龍彦, 今井輝子, 大内清久, 小田切優樹, 平山文俊, 上釜兼人: "Inclusion complex of 3,9-bis (N, N-dimethylcarbamoyloxy)-5H-benzofuro [3,2-c]-quinoline-6-one (KCA-098) with heptakis (2,6-di-O-methyl)-b-cyclodextrin : Interaction and dissolution properties"Chem. Pharm. Bull.. 48. 1264-1269 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 張敬石, 今井輝子, 小田切優樹: "Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin"Arch. Toxicol.. 74. 300-307 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 細川正清, 今井輝子: "カルボキシルエステラーゼの分子多様性とプロドラックの代謝活性化"ファルマシア. 37・2. 119-123 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] T.Imai, M.Taketani, M.Hosokawa, K.Chiba: "Rational design of prodrugs based on the organ-specific esterase activity"3^<rd> Retrometabolism based drug design and targeting conference. 20 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 船戸恵子, 今井輝子, 中島憲一郎, 小田切優樹: "High-performance liquid chromatography with chemiluminescence detection of pebutolol and its hydroxylated metabolite in rat plasma"J. Chromatogr. B757. 229-235 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 森岡雄二朗, 大津麻紀子, 内藤真策, 今井輝子: "Phosphonate O-deethylation of [4-(4-bromo-2-cyano-phenylcarbamoyl)benzyl]-phosphonic acid diethyl ester, a lipoprotein lipase-promoting agent, catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes"Drug Metab. Dispos.. 30. 301-306 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] T. Imai and M. Otagiri: "Steereoselective disposition of compound containing ester based on metabolism by caboxylesterase"Molecular chilarity. 27-30 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] T. Imai, S. Shiraishi and M. Otagiri: "A strategy for the immediate-release of indomethacin from a sustained-release preparation using a chitosan hydrolysate"S.T.P. Pharm. Sci.. 10. 57-62 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] T. Imai, C. Kawasaki, T. Nishiyama and M.Otagiri: "Comparison of the pharmaceutical properties of sustained-release gel beads prepared by alginate having different molecular size with commercial sustained-release tablet"Pharmazie. 5. 218-222 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] T. Imai, S. Kimura and M. Otagiri: "Biological properties of low molecular fragmented gelatine and its evaluation as rapid absorptive additive in human volunteers"S.T.P. Pharm. Sci.. 10. 321-326 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] T. Yamada, T. Imai, K. Ouchi, M. Otagiri, F. Hirayama and K. Uekama: "Inclusino complex of 3,9-bis (N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]-quinoline-6-one (KCA-098) with heptakis (2,6-di-O-mehyl)-β-cyclodextrin : Interaction and dissolution properties"Chem. Pharm. Bull.. 48. 1264-1269 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] J-S. Zhang, T. Imai and M. Otagiri: "Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin"Arch. Toxicol.. 74. 300-307 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M. Hosokawa, T. Imai: "Multiplicity of carboxylesterase isozymes in mammals and human ; role is metabolivc activation of prodrugs"Farumashia. 37. 119-123 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] T. Imai, M. Taketani, M. Hosokawa, K. Chiba: "Rational design of prodrugs based on the organ-specific esterase activity"3rd Retrometabolism based drug design and targeting conference. 20. (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] K. Funato, T. Imai, K. Nakashima and M. Otagiri: "High-performance liquid chromatography with chemiluminescence detection of pebutolol and its hydroxylated metabolite in rat plasma"Chromatogr. B. 757. 229-235 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Y. Morioka, M. Otsu, S. Naito and T. Imai: "Phosphonate O-deethylation of [4-(4-bromo-2-cyano-phenylcarbamoyl)benzyl]-phosphonic acid diethyl ester, a lipoprotein lipase-promoting agent, catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes"Drug Metab. Dispos.. 30. 301-306 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 今井輝子, 大津麻紀子, 大橋邦夫, 武谷恵, 森岡雄二朗, 内藤真策: "高脂血症治療薬NO-1886によるカルボキシルエステラーゼの阻害と加水分解酵素としてのP450"薬剤学. 61・Supplement. 137 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] T.Imai, M.Taketani, M.Hosokawa, K.Chiba: "Rational design of prodrugs based on the organ-specific esterase activity"3^<rd> Retrometabolism based drug design and targeting conference. 20 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 細川正清, 柳沼祐美子, 武谷恵, 今井輝子, 佐々木康綱, 佐藤哲男, 千葉寛: "プロドラッグの代謝活性化に関与するカルボキシルエステラーゼの分子多様性"薬物動態. 16・Supplement. S92-S93 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 武谷恵, 今井輝子: "プロドラッグの初回代謝における小腸カルボキシルエステラーゼの役割 II"薬物動態. 16・Supplement. S231 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 中園由巳, 武谷恵, 今井輝子, 森岡雄二朗, 内藤真策: "高脂血症治療薬NO-1886のラットにおける体内動態:血漿エステラーゼの代謝への寄与"第18回日本薬学会九州支部大会講演要旨集. 149 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 長尾康司, 大橋邦夫, 今井輝子, 森岡雄二朗, 内藤真策: "高脂血漿治療薬NO-1886のヒトにおける加水分解酵素の同定とエステラーゼ阻害作用"第18回日本薬学会九州支部大会講演要旨集. 150 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 今井輝子,小田切優樹: "カルボキシルエステラーゼのキラル代謝に基づく体内動態の種差"シンポジウム「モレキュラー・キラリティ」講演要旨集. 27-30 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 武谷恵,今井輝子: "プロドラッグの初回代謝における小腸カルボキシルエステラーゼの役割"薬物動態. 15・Supplement. 218 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 大橋邦央,武谷恵,内藤真策,今井輝子: "NO-1886によるカルボキシルエステラーゼの阻害"第17回日本薬学会九州支部大会講演要旨集. 52 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 細川正清,今井輝子: "カルボキシルエステラーゼの分子多様性とプロドラッグの代謝活性化"ファルマシア. 37・2. 119-123 (2001)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi